Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma
Status:
Completed
Trial end date:
2020-01-21
Target enrollment:
Participant gender:
Summary
This phase II, single-center study will assess the efficacy of pembrolizumab + nab-paclitaxel
in patients who have metastatic urothelial tumor and do not respond to chemotherapy. The time
between drug administration and progression of the disease will be assessed to determine if
the drug will work.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano